Main Menu

This technology includes plasmodium falciparum parasites (PH1, Benin, FCQ79, Santa Lucia and Borneo) which have all been isolated from infected persons from various geographic locations and have been modified/adapted for growth in the laboratory for multiple uses. Plasmodium falciparum strain W2 is a parasite clone from a parasite isolate called Indochina III/CDC which in turn originated from a patient in Laos infected with chloroquine-resistant parasites. Gametocytes from W2 can be grown experimentally and used in experimental infection of chimpanzees and aotus monkeys.

This technology includes compositions useful as inhibitors of acetyltransferase Eis, whose upregulation causes kanamycin (KAN) resistance of tuberculosis (TB) infections, and therefore can be developed and utilized as a treatment for TB. In particular, the compositions are sulfonamide-based and sulfonyl isothiazole-based small molecules. Drug adjuvants in TB represent a conceptually novel approach to combatting a serious global epidemic of drug-resistant TB.

This technology includes methods for the delivery of active bacteriophages or other agents to the lung, with the goal of reducing bacterial colonization and improving clinical outcomes. This is accomplished by encapsulating, immobilizing, or otherwise incorporating bacteriophages to polymer particles in the micro- to nano-scale size range in order to target their delivery to specific lung regions. The current example of this involves poly(lactic-co-glycolic) acid (PLGA) particles conjugated to phages that kill Pseudomonas aeruginosa in the lungs of cystic fibrosis patients.

This technology includes a Dengue-2 isolated virus for use as a cancer vaccine therapeutic.

This technology includes a repository of unique Enterobacteriaceae isolates for various therapeutic and diagnostic uses:

Enterobacter cloacae (Known Acquired Resistance: NDM-1) – Strain 0038

Klebsiella pneumoniae (Known Acquired Resistance: CTX-M-14) – Strain 0079

Citrobacter freundii (Known Acquired Resistance: KPC-2) – Strain 0116

Escherichia coli (Known Acquired Resistance: NDM-1) – Strain 0118

Klebsiella pneumoniae (Known Acquired Resistance: NDM-1) – Strain 0148

Escherichia coli (Known Acquired Resistance: NDM-5) – Strain 0150

This technology includes therapeutics for Gulf War Illness (GWI). (GWI) patient symptoms, clinical laboratory tests and computational analyses of results from genomic, immunological, autonomic and endocrine changes in animal models therapeutic target were narrowed down to tumor necrosis factor (TNF) and Glucocorticoid receptor for a carefully timed “two hit” treatment model, manipulating cytokine mediated inflammation and the HPA axis.

This technology includes Streptococcus pneumoniae isolates collected through CDC’s Global Strain Bank project with particular serotypes. They were collected as part of routine clinical and surveillance activities and have a wide variety of uses including research, diagnostic, and the development of therapeutics.

This technology includes a new reverse genetics-based approach that generates Crimean-Congo hemorrhagic fever virus (CCHF) viral replicon particles (CCHF VRPs) to be developed into a vaccine for CCHFV. With mortality rates as high as 80% and with no FDA-approved vaccines or therapeutics, CCHFV is considered a dangerous emerging human pathogen. Unlike transcriptionally competent virus like particles (tc-VLPs), that only include CCHFV virus proteins and minigenome RNA, VRPs undergo one full round of replication closely mimicking authentic viral replication.

Summary:

The National Cancer Institute (NCI) seeks licensees to further develop novel exonuclease VII (ExoVII) inhibitors as antibiotic adjuvants for enhancing the efficacy of quinolone antibiotics, particularly in quinolone-resistant bacterial infection.   

This technology includes a novel minigenome assay for arenaviruses that allows for high-throughput screening (HTS) of potential antiviral compounds. To complement to minigenome assay, we have also developed a technique to generate recombinant arenaviruses expressing a reporter protein to allow to HTS of antiviral compounds at BSL-4. This allows for confirmation of potential hits identified by the initial minigenome screen. Human infections with some Arenaviruses such as Lassa (LASV) and Junin (JUNV) virus can result in viral hemorrhagic fever (VHF) disease.